Trince Secures $6,108,565 Seed Funding for Cell-Based Therapeutics

Trince, a spin-off company from Ghent University, has successfully secured $6,108,565 in investment capital from investors.

This funding round marks a pivotal moment for the company as it advances its innovative technology in cell-based science and therapeutics.

The company is dedicated to facilitating the efficient and gentle delivery of molecules into cells, both in vitro and ex vivo.

Its core innovation is the LumiPore transfection platform, which is protected by a portfolio of pending patents.

This technology leverages laser exposure combined with photothermal nanoparticles to convert light energy into heat, transiently permeabilizing the cellular plasma membrane.

The LumiPore platform is designed to deliver a wide variety of effector molecules, such as nucleic acids or proteins, into virtually any cell type.

This includes challenging cell types like immune cells, which are crucial for advanced cell therapies, thereby enhancing the therapeutic quality of the final cell product.

The newly raised capital will be instrumental in accelerating the commercialization and further development of the LumiPore platform.

Trince plans to use the funds to expand its research and development initiatives, strengthen its operational capabilities, and scale its market outreach efforts.

This strategic investment is expected to facilitate broader adoption of its technology within the biotechnology and pharmaceutical sectors.

This significant funding infusion is poised to accelerate Trince's mission to drive advancements in cell-based applications, ultimately improving therapeutic outcomes.

The company is now well-positioned to enhance its impact in the rapidly evolving field of cellular engineering and secure its trajectory for sustained growth.